Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: A multicenter cohort analysis

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3058-3063

  Tarantini, L ^a   Gori, S ^b   Faggiano, P ^c   Pulignano, G ^d   Simoncini, E ^c   Tuccia, F ^a   Ceccherini, R ^e   Bovelli, D ^f   Lestuzzi, C ^g   Cioffi, G ^h  

^a SAN MARTINO HOSPITAL   (Italy)

^b Department of Cardiology   (Italy)

^c Spedali Civili ^*  (Italy)

^d Department of Cardiology   (Italy)

^e ASS 1 Triestina   (Italy)

^f S MARIA HOSPITAL   (Italy)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h Villa Bianca Hospital   (Italy)

Author keywords

Cardiotoxicity; Early HER2 positive breast cancer; Left ventricular ejection fraction; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CARDIOTOXICITY; CLINICAL PRACTICE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; DYSLIPIDEMIA; EARLY CANCER; FEASIBILITY STUDY; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; ITALY; KIDNEY DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTOXINS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HEART DISEASES; HUMANS; HYPERTENSION; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; VENTRICULAR FUNCTION, LEFT;

EID: 84869827588     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds127     Document Type: Article

References (32)

1. Burandt E, Sauter G. HER2 ASCO guidelines. The answer to everything? Pathologe 2010; 31: 285-291.
2. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-69.
3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
4. Andrulis IL, Bull SB, Blackstein ME et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998; 16: 1340-1349.
5. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
7. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27: 5685-5692.
8. Smith I, Procter M, Gelber RD et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36.
9. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
10. Giordano SH, Duan Z, Kuo YF et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24: 2750-2756.
11. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31: 459-467.
12. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-465.
13. Pugatsch T, Abedat S, Lotan C et al. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res 2006; 8: R35.
14. Timolati F, Ott D, Pentassuglia L et al. Neuregulin-1 beta attenuates doxorubicininduced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 2006; 41: 845-854.
15. Doyle JJ, Neugut AI, Jacobson JS et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005; 23: 8597-8605.
16. Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25: 3808-3815.
17. Du XL, Xia R, Liu CC et al. Cardiac toxicity associated with anthracyclinecontaining chemotherapy in older women with breast cancer. Cancer 2009; 115: 5296-5308.
18. Héry C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008; 19: 1187-1194.
19. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf
20. Senni M, Tribouilloy CM, Rodeheffer RJ et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-2289.
21. Graham I, Atar D, Borch-Johnsen K et al. European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG).: European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375-2414.
22. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720-2726.
23. Al-Refaie WB, Vickers SM, Zhong W et al. Cancer trials versus the real world in the United States. Ann Surg 2011; 254: 438-442.
24. Guglin M, Hartlage G, Reynolds C et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail 2009; 15: 651-657.
25. Wadhwa D, Fallah-Rad N, Grenier D et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009; 117: 357-364.
26. Mustacchi G, Cazzaniga ME, Pronzato P et al. Adjuvant chemotherapy for early breast cancer in Italy: what has changed today versus the early 2000's. A comparison between two observational national studies: NORA and NEMESI. Ann Oncol 2010; 21: (Suppl 8):| viii84 abstracts.
27. Wildiers H, Kunkler I, Biganzoli L et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007; 8: 1101-1115.
28. Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat 2012; 131: 371-383.
29. Mackey JR, Clemons M, Côté MA et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008; 15: 24-35.
30. Reynolds CC, Hartlage G, Chen R et al. Can heart failure medications prevent trastuzumab-induced cardiotoxicity? J Cardiac Failure 2009; 15: 651-657.
31. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48: 2258-2262.
32. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910-3916.